AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02296437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation combined with cognitive training
Study NCT02126943 — intervention group
Intervention type: DRUG
Intervention: Opsumit (macitentan)
Description: 10 mg tablets
Study NCT04117737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality combined with anti-gravity treadmill
Description: The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system.~The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life.
Study NCT01495338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.17%
Description: 1 drop in one eye at one timepoint
Study NCT01495338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24% (Formulation 1)
Description: 1 drop in one eye at one timepoint
Study NCT01495338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24% (Formulation 2)
Description: 1 drop in one eye at one timepoint
Study NCT01495338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine hydrochloride 0.2%/Tears Naturale II
Description: 1 drop in one eye at one timepoint
Study NCT02456376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory Integration Testing
Description: Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
Study NCT02456376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Integration Testing
Description: Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
Study NCT02456376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SR stimulation & Sensory integration testing
Description: Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
Study NCT02456376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SR stimulation & Sensory integration testing
Description: Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
Study NCT02710682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-open surgery
Description: This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.~1. Skin disinfection; Local anesthesia (lidocaine 1%).~2. Skin incision, slightly anterior to lateral epicondyle.~3. Exposure of the plane between the tendon and fascia.~4. Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.~5. Excision of diseased tissue of the ECRB tendon.~6. ECRL tendon is sutured back to the fascia. The skin is closed.~7. Patient is monitored for 30 minutes after procedure.
Study NCT02710682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Tendon fenestration
Description: This treatment will be administered by a fellowship-trained MSK radiologist.~1. Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.~2. Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.~3. Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.~4. Patient monitored for 30 minutes, before being discharged.
Study NCT00221962 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: Open label
Study NCT01016691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Drug Device
Description: device inserted for 4 days
Study NCT01016691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Drug Device
Description: device inserted for 4 days
Study NCT01016691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Device
Description: device inserted for 4 days
Study NCT04426500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided transversus abdominus plane block
Description: bilateral TAP using laparoscopic guidance in prostatectomies
Study NCT00629850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerlung Performer
Description: Inspiratory/Expiratory muscle trainer
Study NCT00780299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemodialysis with high permeability (HDHP)
Description: HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
Study NCT00780299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH
Description: hemofiltration intermittent dialysis
Study NCT03437850 — intervention group
Intervention type: OTHER
Intervention: Usual care
Description: Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
Study NCT02699385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Therapy
Description: Each participants will initiate ORT in the physician's office on Day 1.
Study NCT01981499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999
Description: Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
Study NCT01981499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT01981499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg MR PF-05180999
Description: Single 120 mg dose administered as modified release formulation
Study NCT01981499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 360 mg MR PF-05180999
Description: Single 360 mg dose administered as modified release formulation
Study NCT01981499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Description: Single 10 mg dose of cetirizine
Study NCT01981499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study NCT01207440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.
Study NCT02356991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Study NCT02356991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01405287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTCA with stent placement
Description: PTCA with stent placement (Drug Eluting Stent)
Study NCT01405287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA with stent placement
Description: PTCA with stent placement (Drug Eluting Stent)
Study NCT02447159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfers
Description: Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
Study NCT03827928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga/meditation
Description: A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
Study NCT01312311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin
Description: Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1
Study NCT01016691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Description: one drop in each eye on one day only
Study NCT01016691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03%
Description: one drop in each eye on one day only
Study NCT03812523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60 mg qd
Description: 60 mg tablet Taken by mouth, Once Daily for 180 Days
Study NCT04340778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
Study NCT01842022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isomaltulose
Description: Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
Study NCT02214420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simeprevir
Study NCT02214420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Study NCT02214420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT03812523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: 10 mg tablet Taken by mouth Twice Daily for 180 Days
Study NCT01012557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Focetria
Description: 7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
Study NCT01012557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Focetria
Description: 3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
Study NCT03905629 — intervention group
Intervention type: OTHER
Intervention: None (retrospective observational study)
Description: This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay >15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~* Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~* Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~* Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors
Study NCT00796133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NES/E2 gel
Description: Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P\<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
Study NCT01012557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Focetria
Description: 15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
Study NCT01012557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Focetria
Description: 7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
Study NCT03626506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
Study NCT03626506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide
Description: After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
Study NCT03626506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
Study NCT03626506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
Study NCT02140307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response-based Mental Health Promotion (RR-MHP)
Description: The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship).
Study NCT02140307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response-based Mental Health Promotion (RR-MHP)
Description: The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship).
Study NCT01560507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline (Chantix)
Description: For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
Study NCT01560507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion (Zyban)
Description: After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
Study NCT01560507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patches
Description: 21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
Study NCT01842022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sucrose
Description: Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
Study NCT01842022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Glucose
Description: Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
Study NCT02506608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operation of sensorized hand prosthesis
Description: Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention.
Study NCT06557226 — intervention group
Intervention type: OTHER
Intervention: oral and nutritional examination
Description: Participants will receive a comprehensive oral examination, nutritional examination and will fill an oral health related quality of life questionnaire.
Study NCT00674362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
Study NCT01231750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
Study NCT00674362 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
Study NCT02738060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.~Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study.
Study NCT01231750 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: cream, 4cm spread over 8cm x 15cm area of skin
Study NCT03545191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Description: Daridorexant will be administered as tablets, orally, once daily in the evening.
Study NCT03545191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Description: Daridorexant will be administered as tablets, orally, once daily in the evening.
Study NCT03545191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablets, orally, once daily in the evening.
Study NCT00604903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of Pressure sensor.
Description: Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
Study NCT03829358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum IS-10506
Description: Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.
Study NCT03829358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fermented milk containing placebo to be consumed once daily for three weeks.
Study NCT00875875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
Study NCT00920088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir
Description: DRV/RTV 600/100mg
Study NCT00920088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: LPV/RTV 400/100mg
Study NCT00920088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 3mg
Study NCT00920088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan 30mg
Study NCT00920088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Flurbiprofen 50mg
Study NCT00920088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: NNRTI under investigation
Study NCT01655524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASSUAGE Protocol
Description: 75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
Study NCT02593227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose FRα vaccine
Description: 165ug per peptide ID injection
Study NCT02593227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion over 1 hour
Study NCT02593227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose FRα vaccine
Description: 500ug per peptide ID injection